Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: Meningitis in Burkina Faso

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Somda, Zana C ^a   Perry, Helen N ^a   Messonnier, Nancy R ^a   Djingarey, Mamadou H ^b   Ki, Salimata Ouedraogo ^c   Meltzer, Martin I ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b World Health Organization Ouagadougou   (Burkina Faso)

^c MINISTÈRE DE LA SANTÉ   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BURKINA FASO; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; EPIDEMIC; EPIDEMIC MENINGITIS; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MORTALITY; PUBLIC HEALTH; RISK REDUCTION;

BURKINA FASO; COST-BENEFIT ANALYSIS; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MODELS, ECONOMIC; POPULATION SURVEILLANCE;

EID: 77958551128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013044     Document Type: Article

References (35)

1. Fauci AS (2001) Infectious diseases: considerations for the 21st century. Clin Infect Dis 32: 657-685.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757.
3. Worrall E, Rietveld A, De la Collette C (2004) The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situation in Africa. Am J Trop Med Hyg 71(suppl. 2): 136-140.
4. Campagne G, Schuchat A, Djibo S, Ousséini A, Cissé L, et al. (1999) Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull World Health Organ 77: 499-508.
5. Mohammed I, Nasidi A, Alkali AS, Garbati MA, Ajayi-Obe EK, et al. (2000) A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans Royal Soc Trop Med Hyg 94: 265-270.
6. Lapeyssonnie L (1963) La meningite cerebro-spinale en Afrique. Bull World Health Organ 28(suppl): 3-114.
7. Kaninda AV, Belanger F, Lewis R, Batchassi E, Aplogan A, et al. (2000) Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. Int J Epidemiol 29: 933-940.
8. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C (2001) Timely detection of meningococcal meningitis epidemics in Africa. The Lancet 358: 287-293.
9. Robbins J, Towe DW, Gotschlich EC, Schneerson R (1997) ''Love's labours lost'': failure to implement mass vaccination against Group A meningococcal meningitis in sub-Saharan Africa. The Lancet 350: 880-882.
10. Morel CM, Lauer JA, Evans DB (2005) Achieving the millennium development goals for health: Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ, doi: 10.1136/bmj.38639.702384.AE (published 10 November.
11. Sachs J, Malaney P (2002) The economic and social burden of malaria. Nature 415: 680-685.
12. Chima RI, Goodman CA Mills A (2003) The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 63: 17-36.
13. Russel S (2004) The economic burden of illness for households in developing countries: A review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 71(Suppl 2): 147-155.
14. World Health Organization, Regional Office for Africa (1999) Integrated Disease Surveillance and Response: A Regional Strategy for Communicable Diseases 1999 - 2003. Available: http://www.afro.who.int/en/clusters-aprogrammes/dpc/integrated-disease-surveillance/cds-publications.html. Accessed 2010 Sept 05.
15. World Health Organization, Regional Office for Africa, Centers for disease Control and Prevention (2002) Technical Guidelines for Integrated Disease Surveillance and Response in the African Region. Available: http://www.cdc.gov/idsr/resources.html. Accessed 2010 Sept 05.
16. Perry NH, McDonnell MS, Alemu W, Nsubuga P, Chungong S, et al. (2007) Planning an integrated disease surveillance and response system: a matrix of skills and activities. BMC Medicine 5: 24. doi: 10.1186/1741-7015-5-24.
17. Walker D, Fox-Rushby JA (2000) Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Economics 9: 681-698.
18. Hutibessy RCW, Bendib LM, Evans DB (2001) Critical issues in the economic evaluation of interventions against communicable diseases. Acta Tropica 78: 191-206.
19. Uzicanin A, Zhou F, Eggers R, Webb E, Strebel P (2004) Economic Analysis of the 1996-1997 mass measles immunization campaigns in South African. Vaccine 22: 3419-3426.
20. Wilkins JJ, Folb PI, Valentine N, Barnes KI (2002) An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: development of a model for estimating the recurrent direct costs. Trans R Soc Trop Med Hyg 96: 85-90.
21. Parent du Chatelet I, Gessner BD, da Silva A (2001) Comparison of costeffectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 19: 3420-3431.
22. Khan MM, Khan SH, Walker D, Fox-Rushby J, Cutts F, et al. (2004) Cost of delivering child immunization services in urban Bangladesh: a study based on facility-level surveys. J Health Popul Nutr 22: 404-412.
23. Miller MA, Shahab CA (2006) Review of the cost effectiveness of immunization strategies for the control of epidemic of meningococcal meningitis. Pharmacoecon 23: 333-343.
24. John TJ, Samuel, Balraj V, John R (1998) Disease surveillance at district level: a model for developing countries. The Lancet 352: 58-61.
25. Elbasha EH, Fitzsimmons TD, Meltzer MI (2000) Costs and benefits of a subtype-specific surveillance system for identifying Escherichia coli o157: H7 outbreaks. Emerg Infect Dis 6: 293-297.
26. Somda ZC, Meltzer MI, Perry HN, Messonnier NE, Abdulmumini U (2009) Cost analysis of an integrated disease surveillance and response system: case of Burkina Faso, Eritrea and Mali. Cost Eff Resour Alloc 7: 1. doi: 10.1186/1478-7547-7-1.
27. International Monetary Fund. World Economic and Financial Surveys, World Economic Outlook Database. Available: http://www.imf.org/external/pubs/ft/weo/2006/02/data/index.aspx. Accessed 2006 November 7.
28. Smith AW, Bradley AK, Wall RA, McPherson B, Secka A, et al. (1988) Sequelae of epidemic meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 82: 312: 320.
29. World Health Organization (2000) Detecting meningococcal meningitis epidemics in highly-endemic African countries: WHO recommendation. Weekly Epidemiol Rep 75: 306-309.
30. Bovier PA, Wyss K, Au HJ (1999) A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. Soc Sci Med 48: 1205-1220.
31. Monath TP and, Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg 1993 48: 247-299.
32. Robertson RL, Foster SO, Hull HF, Williams PJ (1985) Cost-effectiveness of immunization in The Gambia. J Trop Med Hyg 88: 343-351.
33. Taha M-K, Parent du Chatelet I, Schlumberger M, Sanou I, Djibo S, et al. (2002) Neisseria meningitidis Serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 40: 1083-1084.
34. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA (2005) Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 43: 5129-5135.
35. Nicolas P, Décousset L, Riglet V, Castelli P, Stor R, et al. (2001) Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in Serogroup A meningococci, Africa. Emerg Infect Dis 7: 849-854.